A high-frequency clinical oncology journal formerly from Future Medicine and now published by Taylor & Francis. It carries trial protocols, reviews and original research and is read by clinical oncologists and industry researchers.
Future Oncology is published by Taylor & Francis (Informa UK). The NLM Catalog records that it began in 2005 in London with Future Medicine Ltd, moved to Taylor & Francis in 2024, increased from thirty-six issues a year (2019 to 2021) to forty issues a year from 2022, and is indexed in MEDLINE with content deposited in PubMed Central. Crossref lists Informa UK (Taylor & Francis) as publisher.
GU oncologist who led TALAPRO-2 and other trials combining PARP inhibitors with hormone therapy.
Sara López-Tarruella is a breast oncologist leading GEICAM neoadjuvant studies in triple-negative disease.
Medical oncologist who is Executive Director of the NCI-designated Greenebaum Comprehensive Cancer Center at the University of Maryland in Baltimore.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/